What do doctors prescribe for hot flashes? Estrogen, or 3 approved non-hormonal drugs
For hot flashes, the first-line treatment is hormone therapy: estrogen, plus progesterone or a progestin if you have a uterus. The Menopause Society calls it the most effective treatment. For women who can't or prefer not to take estrogen, the FDA has approved three non-hormonal drugs: low-dose paroxetine (Brisdelle), fezolinetant (Veozah) and elinzanetant (Lynkuet).
Where to get a hot flash prescription online
Gala prescribes estradiol pills and patches, with progesterone if needed, and lists non-hormonal options. The clinician review is included.
How we picked
Every program here is prescribed online by a US-licensed clinician, lets you start without an office visit. Each card shows the price we read on the program's own site (or says when a program prices only after its intake) and what that price covers, and we keep the date of every read; some programs bill a membership and the medication separately, and the card says so. The label on each card says what that program stands out for. How we check prices and programs.
- Hormone and non-hormonal options
From $69/mo, all includedPill, patch, cream or hormone-free: your clinician builds the plan
- Estradiol pill or patch, progesterone if needed, vaginal estradiol or non-hormonal options
- A US-licensed clinician reviews a 5-minute assessment; reviewed and shipped within days, per Gala
- Free shipping, dose adjustments and messaging included; FSA/HSA; cancel anytime
Comes asTablet or patch or cream
From$69/moall included, no insurance needed4.6 on Trustpilot4,257 reviews ·Visit Gala Read our Gala review
Hot flash prescriptions: FDA status and what each is for
| Option | Type | FDA status for hot flashes | Menopause Society view | Label caution | At programs we compare |
|---|---|---|---|---|---|
| Estrogen (estradiol pill, patch, gel, spray, ring) | Hormone | FDA-approved for hot flashes | Most effective treatment (2022, 2023) | With a uterus, needs progesterone or a progestin; systemic estrogen-alone labels keep an endometrial cancer boxed warning | Gala: estradiol pill or patch, with progesterone if needed |
| Conjugated estrogens + bazedoxifene (Duavee) | Hormone in one tablet | Approved October 3, 2013, for women with a uterus | Part of hormone therapy | Label: do not take additional estrogens | Not listed |
| Compounded "bioidentical" hormones | Hormone, custom-mixed | Not FDA-approved | "Not safer or more effective than approved bioidentical hormones" | No FDA label | Not listed |
| Low-dose paroxetine 7.5 mg (Brisdelle) | Non-hormonal (SSRI) | Approved June 28, 2013 | SSRIs recommended (Level I) | Boxed warning on suicidal thoughts; may lower tamoxifen's effect | Gala lists non-hormonal options but does not name them |
| Fezolinetant (Veozah) | Non-hormonal (NK3 blocker) | Approved May 12, 2023 | Recommended (Level I) | Boxed warning for liver injury since December 2024; liver tests before and during treatment | Gala lists non-hormonal options but does not name them |
| Elinzanetant (Lynkuet) | Non-hormonal (NK1 and NK3 blocker) | Approved October 24, 2025 | Approved after the 2023 statement | Not for use in pregnancy; can cause sleepiness; bloodwork before starting; seizures have been reported | Gala lists non-hormonal options but does not name them |
| Other SSRIs and SNRIs | Antidepressants, off-label | Not approved for hot flashes | Recommended (Level I) | Antidepressant boxed warning | Gala lists non-hormonal options but does not name them |
| Gabapentin | Off-label | Not approved for hot flashes | Recommended (Level I) | Not covered here | Not listed |
| Oxybutynin | Off-label | Not approved for hot flashes | Recommended (Levels I-II) | Not covered here | Not listed |
| Clonidine | Off-label | Not approved for hot flashes | Not recommended (Levels I-III) | Not covered here | Not listed |
| Pregabalin | Off-label | Not approved for hot flashes | Not recommended (Level III) | Not covered here | Not listed |
| Supplements and herbal remedies | Not prescription drugs | Not FDA-approved | Not recommended (Levels I-II) | Not covered here | Not listed |
Sources: 2023 nonhormone therapy position statement (levels of evidence I to III); 2022 hormone therapy position statement; Drugs@FDA; Brisdelle, Veozah, Lynkuet and Duavee labels. Read Nov 8, 2026. Gala's offer from its own page.
Hormone therapy for hot flashes: who it suits
The 2022 position statement says hormone therapy "remains the most effective treatment for vasomotor symptoms", the medical name for hot flashes and night sweats. For women younger than 60 or within 10 years of menopause onset with no contraindications, it calls the benefit-risk ratio favorable. Estrogen for the whole body comes as pills, skin patches, gels, sprays and a vaginal ring. With a uterus, progesterone or a progestin is added; Duavee pairs estrogen with bazedoxifene in one tablet instead.
Since November 10, 2025, the FDA has been removing heart disease, breast cancer and dementia wording from the boxed warning on these labels, product by product. The endometrial cancer warning stays on systemic estrogen-alone products. Low-dose vaginal estrogen treats vaginal symptoms, not hot flashes; that and who should avoid hormones are covered in what doctors prescribe for menopause.
Sources: 2022 statement; womenshealth.gov; FDA announcement, November 10, 2025; Duavee label.
The three non-hormonal drugs the FDA approved for hot flashes
- Brisdelle (paroxetine mesylate), approved June 28, 2013. The label lists 7.5 mg once daily at bedtime, a lower dose than paroxetine for depression. It carries the antidepressant boxed warning, and the label says it may reduce how well tamoxifen works.
- Veozah (fezolinetant), approved May 12, 2023. It is an NK3 receptor antagonist. In December 2024 the FDA added a boxed warning for rare but serious liver injury. The label calls for liver tests before starting, monthly for the first 3 months, then at 6 and 9 months.
- Lynkuet (elinzanetant), approved October 24, 2025. It is an NK1 and NK3 receptor antagonist. The label lists two 60 mg capsules once daily at bedtime. It is not for use in pregnancy, can cause sleepiness, and needs bloodwork for the liver before starting. The label also warns that seizures have been reported in people taking it and advises caution in anyone with a history of seizures.
Sources: Drugs@FDA; Brisdelle label, sections 2, 5 and 7; Veozah label, boxed warning and section 2; FDA Drug Safety Communication, updated December 16, 2024; Lynkuet label, sections 2, 4 and 5 (including 5.4, risk of seizure).
Off-label prescriptions doctors use for hot flashes
The Menopause Society's 2023 nonhormone statement recommends other SSRIs and SNRIs and gabapentin at its highest level of evidence (Level I), and oxybutynin at Levels I-II. None of these is FDA-approved for hot flashes, so a doctor prescribes them off-label. They are an option when estrogen is ruled out, for example after some cancers, or when a woman would rather not take hormones.
Source: 2023 nonhormone therapy position statement.
What the Menopause Society does not recommend for hot flashes
The same statement does not recommend clonidine (Levels I-III) or pregabalin (Level III), even though both are prescription drugs. It also does not recommend supplements and herbal remedies, soy foods and extracts, or cannabinoids. Among non-drug options it recommends cognitive-behavioral therapy and clinical hypnosis (Level I), and weight loss and stellate ganglion block (Levels II-III).
Source: 2023 nonhormone therapy position statement, abstract.
After breast cancer or on tamoxifen
The 2023 statement names estrogen-dependent cancers as a reason a woman may not be a good candidate for hormone therapy. Brisdelle's label warns that paroxetine may lower tamoxifen's effect, so the drug you take for breast cancer matters when choosing a non-hormonal option. These decisions belong with your oncology team.
Sources: 2023 statement, conclusion; Brisdelle label, section 5.
Getting a hot flash prescription online
Gala's page lists hot flashes and night sweats among the symptoms it treats, prescribes estradiol as a pill or patch, with progesterone if needed, and lists non-hormonal options without naming the drugs. A US-licensed clinician reviews a 5-minute assessment, and Gala says labs are usually not needed. It accepts FSA and HSA cards. Compounded custom hormones are not FDA-approved; The Menopause Society says they "are not safer or more effective than approved bioidentical hormones." Another menopause program we have reviewed: Winona.
Sources: Gala's own page, read Nov 8, 2026; The Menopause Society, Hormone therapy. More on Gala: Gala review.
Hot flash prescriptions: questions
Is there a non-hormonal prescription for hot flashes?
Yes, three are FDA-approved for moderate to severe hot flashes: low-dose paroxetine (Brisdelle), fezolinetant (Veozah) and elinzanetant (Lynkuet). Doctors also prescribe other SSRIs and SNRIs, gabapentin or oxybutynin off-label, which the 2023 Menopause Society statement recommends.
What is the new hot flash drug?
The newest is elinzanetant (Lynkuet), approved by the FDA on October 24, 2025. Its label calls it an NK1 and NK3 receptor antagonist. Fezolinetant (Veozah), approved in May 2023, is an NK3 receptor antagonist.
Related: What doctors prescribe for menopause · Best online HRT for menopause